IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
In 2021, the World Health Organization classified isocitrate dehydrogenase (<i>IDH</i>) mutant gliomas as a distinct subgroup of tumors with genetic changes sufficient to enable a complete diagnosis. Patients with an <i>IDH</i> mutant glioma have improved survival which has b...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/13/11/885 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850267759345139712 |
|---|---|
| author | Kristian A. Choate Evan P. S. Pratt Matthew J. Jennings Robert J. Winn Paul B. Mann |
| author_facet | Kristian A. Choate Evan P. S. Pratt Matthew J. Jennings Robert J. Winn Paul B. Mann |
| author_sort | Kristian A. Choate |
| collection | DOAJ |
| description | In 2021, the World Health Organization classified isocitrate dehydrogenase (<i>IDH</i>) mutant gliomas as a distinct subgroup of tumors with genetic changes sufficient to enable a complete diagnosis. Patients with an <i>IDH</i> mutant glioma have improved survival which has been further enhanced by the advent of targeted therapies. <i>IDH</i> enzymes contribute to cellular metabolism, and mutations to specific catalytic residues result in the neomorphic production of D-2-hydroxyglutarate (D-2-HG). The accumulation of D-2-HG results in epigenetic alterations, oncogenesis and impacts the tumor microenvironment via immunological modulations. Here, we summarize the molecular, cellular, and clinical implications of <i>IDH</i> mutations in gliomas as well as current diagnostic techniques. |
| format | Article |
| id | doaj-art-c64d148d117148e9be1d87950c295c2b |
| institution | OA Journals |
| issn | 2079-7737 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj-art-c64d148d117148e9be1d87950c295c2b2025-08-20T01:53:40ZengMDPI AGBiology2079-77372024-10-01131188510.3390/biology13110885IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsKristian A. Choate0Evan P. S. Pratt1Matthew J. Jennings2Robert J. Winn3Paul B. Mann4Upper Michigan Brain Tumor Center, Northern Michigan University, Marquette, MI 49855, USAUpper Michigan Brain Tumor Center, Northern Michigan University, Marquette, MI 49855, USAUpper Michigan Brain Tumor Center, Northern Michigan University, Marquette, MI 49855, USAUpper Michigan Brain Tumor Center, Northern Michigan University, Marquette, MI 49855, USAUpper Michigan Brain Tumor Center, Northern Michigan University, Marquette, MI 49855, USAIn 2021, the World Health Organization classified isocitrate dehydrogenase (<i>IDH</i>) mutant gliomas as a distinct subgroup of tumors with genetic changes sufficient to enable a complete diagnosis. Patients with an <i>IDH</i> mutant glioma have improved survival which has been further enhanced by the advent of targeted therapies. <i>IDH</i> enzymes contribute to cellular metabolism, and mutations to specific catalytic residues result in the neomorphic production of D-2-hydroxyglutarate (D-2-HG). The accumulation of D-2-HG results in epigenetic alterations, oncogenesis and impacts the tumor microenvironment via immunological modulations. Here, we summarize the molecular, cellular, and clinical implications of <i>IDH</i> mutations in gliomas as well as current diagnostic techniques.https://www.mdpi.com/2079-7737/13/11/885isocitrate dehydrogenase<i>IDH1</i><i>IDH2</i>D-2-HydroxyglutarateD-2-HGepigenetics |
| spellingShingle | Kristian A. Choate Evan P. S. Pratt Matthew J. Jennings Robert J. Winn Paul B. Mann IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications Biology isocitrate dehydrogenase <i>IDH1</i> <i>IDH2</i> D-2-Hydroxyglutarate D-2-HG epigenetics |
| title | IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications |
| title_full | IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications |
| title_fullStr | IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications |
| title_full_unstemmed | IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications |
| title_short | IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications |
| title_sort | idh mutations in glioma molecular cellular diagnostic and clinical implications |
| topic | isocitrate dehydrogenase <i>IDH1</i> <i>IDH2</i> D-2-Hydroxyglutarate D-2-HG epigenetics |
| url | https://www.mdpi.com/2079-7737/13/11/885 |
| work_keys_str_mv | AT kristianachoate idhmutationsingliomamolecularcellulardiagnosticandclinicalimplications AT evanpspratt idhmutationsingliomamolecularcellulardiagnosticandclinicalimplications AT matthewjjennings idhmutationsingliomamolecularcellulardiagnosticandclinicalimplications AT robertjwinn idhmutationsingliomamolecularcellulardiagnosticandclinicalimplications AT paulbmann idhmutationsingliomamolecularcellulardiagnosticandclinicalimplications |